^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CCDC6-RET fusion

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1, CCDC6, Coiled-Co
Entrez ID:
1m
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer. (PubMed, NPJ Precis Oncol)
We previously showed that the multi-kinase inhibitors vandetanib and cabozantinib increase the mitochondrial membrane potential (Δψm) in RET-mutated thyroid tumor cells and that this effect can be exploited to increase mitochondrial enrichment of Δψm-sensitive agents in the tumor cells...The quality of life of one patient significantly improved over a year until the tumor relapsed. This combination of selpercatinib with MitoQ may have therapeutic potential for patients with RET-mutated tumors and intolerant to regular selpercatinib doses.
Journal
|
RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • RET mutation • CCDC6-RET fusion • RET M918T
|
Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib)
2ms
Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer. (PubMed, Heliyon)
Of four patients with PD-L1 overexpression (>50%) one received pembrolizumab and the other three patients received pemetrexed, carboplatin, and pembrolizumab or camrelizumab. Fifteen patients received selective RET inhibitors (pralsetinib and selpercatinib), resulting in an ORR of 53.3% (8/15) and median PFS of 10.0 months (95% CI 5.2-14.9). ICIs for PD-L overexpression and treatment naive patients offer comparable benefits for RET fusion-positive NSCLC, warranting further investigation.
Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
|
PD-L1 (Programmed death ligand 1) • RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B) • CCDC6 (Coiled-Coil Domain Containing 6) • NCOA4 (Nuclear Receptor Coactivator 4)
|
PD-L1 overexpression • RET fusion • KIF5B-RET fusion • CCDC6-RET fusion • NCOA4-RET fusion • RET positive
|
Keytruda (pembrolizumab) • carboplatin • AiRuiKa (camrelizumab) • Retevmo (selpercatinib) • pemetrexed • Gavreto (pralsetinib)
3ms
Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer. (PubMed, Cancer Med)
NGS after EGFR-TKI resistance may detect targetable drivers besides T790M. To do either liquid or tissue NGS only could miss patients with T790M. To do tissue and liquid NGS in parallel after EGFR-TKI resistance may find more patients with targetable cancers.
Journal • Next-generation sequencing
|
HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
|
HER-2 amplification • MET amplification • EGFR T790M • RET fusion • CCDC6-RET fusion • EGFR T790M negative
|
Tagrisso (osimertinib)
6ms
Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification. (PubMed, PeerJ)
We provide further evidence for using molecular risk stratification as a promising predictor of disease outcomes. The results of this study may be limited by the extremely high prevalence of cancer in the cohort for clinical reference.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RET (Ret Proto-Oncogene) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCDC6 (Coiled-Coil Domain Containing 6) • RAS (Rat Sarcoma Virus)
|
KRAS mutation • BRAF mutation • NRAS mutation • RET fusion • RET mutation • CCDC6-RET fusion
9ms
Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial. (PubMed, JCO Precis Oncol)
Selpercatinib demonstrated clinically meaningful and durable intracranial activity in Chinese patients with brain metastases from RET-altered NSCLC, consistent with the global LIBRETTO-001 trial.
P2 data • Journal • Metastases
|
RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B) • CCDC6 (Coiled-Coil Domain Containing 6) • NCOA4 (Nuclear Receptor Coactivator 4)
|
RET fusion • CCDC6-RET fusion • NCOA4-RET fusion • RET positive
|
Retevmo (selpercatinib)
11ms
Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation. (PubMed, Oncologist)
This is the first case in the literature of metastatic TNBC with CCDC6-RET fusion treated with pralsetinib, an RET-specific antagonist. This case demonstrates the potential efficacy of pralsetinib in cases of TNBC with RET fusion mutations and suggests that NGS may reveal new opportunities and bring new therapeutic interventions to patients with refractory TNBC.
Journal
|
RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • RET mutation • CCDC6-RET fusion • RET expression
|
Gavreto (pralsetinib)
almost1year
Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases. (PubMed, Thorac Cancer)
The cobas EGFR Mutation Test, ddPCR, and NGS appear to be feasible methods for analyzing CSF ctDNA in patients with NSCLC and LM. In addition, NGS may provide comprehensive information regarding the mechanisms underlying osimertinib resistance.
Journal
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
|
EGFR mutation • MET amplification • RET fusion • CCDC6-RET fusion • MET mutation
|
cobas® EGFR Mutation Test v2
|
Tagrisso (osimertinib)
over1year
Adversary of DNA integrity: a long non-coding RNA stimulates driver oncogenic chromosomal rearrangement in human thyroid cells. (PubMed, Int J Cancer)
We found that CASTL1 expression is elevated in tumors with CCDC6-RET fusion which is the most frequent rearrangement in papillary thyroid carcinoma. Our results open a new venue for the studies of early oncogenesis in various tumor types, especially those associated with physical or chemical DNA damage.
Journal
|
RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6) • CAST (Calpastatin)
|
RET fusion • CCDC6-RET fusion
over1year
Reversing "Flip-Flop" Phenomenon of 131I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib. (PubMed, Clin Nucl Med)
Reduced FDG avidity of those lesions and decreased serum antithyroglobulin antibody titer were also noticed. This case illustrated successfully reinduced 131I avidity in papillary thyroid cancer through redifferentiation with target therapy to suppress tumor RET overexpression.
Journal
|
RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • CCDC6-RET fusion • RET overexpression • RET positive
|
Gavreto (pralsetinib)
over1year
Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells. (PubMed, Biochem Biophys Res Commun)
Moreover, we found that most LUAD cell lines and tissues expressed high levels of BCL2L1 and MCL1 mRNA but extremely low levels of BCL2. Together, these findings suggest that inhibiting BCL2L1 plus MCL1 may represent a new approach to treating LUAD cells irrespective of their driver mutations.
Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • BCL2 (B-cell CLL/lymphoma 2) • CCDC6 (Coiled-Coil Domain Containing 6) • BCL2L1 (BCL2-like 1)
|
MET amplification • RET fusion • MET exon 14 mutation • RET mutation • CCDC6-RET fusion • BCL2 expression • MCL1 expression • RET positive
over1year
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study. (PubMed, Target Oncol)
We confirmed the efficacy of osimertinib in patients with advanced EGFR mutation-positive NSCLC. At progression, the most frequent histomolecular alterations were MET amplification and EGFR C797S mutation.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
|
EGFR mutation • MET amplification • RET fusion • EGFR C797S • CCDC6-RET fusion
|
Tagrisso (osimertinib)
over1year
An integrative pan cancer analysis of RET aberrations and their potential clinical implications. (PubMed, Sci Rep)
Two FDA-approved RET inhibitors-pralsetinib and selpercatinib have been implied for the treatment of patients with RET S891L mutant UCEC and the treatment of patients with metastatic RET-fusion positive THCA and non-small cell lung cancer (NSCLC) at therapeutic level 1. At last, patients with higher expression and sequence variant frequency have a worse prognosis, such as sarcoma patients. This work provided a profound and comprehensive analysis of RET and co-occurred alterations, RET mRNA expression and the clinical significance in pan cancer, offering new insights into targeted therapy for patients with RET anomalies.
Journal • BRCA Biomarker • Pan tumor
|
TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6) • BRCA (Breast cancer early onset) • TGFB1 (Transforming Growth Factor Beta 1)
|
TP53 mutation • RET fusion • RET mutation • CCDC6-RET fusion • RET M918T • RET expression • RET positive
|
Retevmo (selpercatinib) • Gavreto (pralsetinib)
over1year
RET Fusions as Primary Oncogenic Drivers and Secondary Acquired Resistance to EGFR TKI in a Large Cohort of Non-Small-Cell Lung Cancers (IASLC-WCLC 2022)
Our study systematically evaluated the genetic landscape underlying RET fusions as a rare driver gene and provide important insights into secondary resistance to EGFR TKIs in Chinese NSCLCs, which will be important considerations in improving the efficacy and clinical outcome of existing RET inhibitors and facilitating the development of new therapeutics.
Preclinical
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • KIF5B (Kinesin Family Member 5B) • MDM2 (E3 ubiquitin protein ligase) • CCDC6 (Coiled-Coil Domain Containing 6) • SMAD4 (SMAD family member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NCOA4 (Nuclear Receptor Coactivator 4)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RET fusion • RET mutation • KIF5B-RET fusion • CCDC6-RET fusion • CDKN2A mutation • NCOA4-RET fusion • EGFR mutation + RET fusion • EGFR fusion • RET positive
|
Tagrisso (osimertinib)
over1year
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. (PubMed, JTO Clin Res Rep)
No grade greater than or equal to 4 adverse events were observed. Lorlatinib induced durable intracranial responses in patients with ROS1-rearranged NSCLC and prior isolated CNS progression on crizotinib.
P2 data • Journal
|
RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • ROS1 fusion • CCDC6-RET fusion • ROS1 rearrangement • ROS1 G2032R • ROS1 L2086F • ROS1 G2032R + ROS1 L2086F
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
2years
Simultaneous tissue and liquid next-generation sequencing after first-line EGFR tyrosine kinase inhibitors resistance in advanced non-small cell lung cancer (ELCC 2022)
15 received gefitinib, 27 received erlotinib, 16 received afatinib and 2 received osimertinib as the first-line therapy...One patient with MET CNG kept erlotinib and added-on capmatinib...Non-detectable variant in cfDNA NGS might predict better outcome in T790M-positive patients. Legal entity responsible for the study The authors.
Clinical • Next-generation sequencing
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
|
EGFR L858R • EGFR exon 19 deletion • EGFR T790M • RET fusion • CCDC6-RET fusion
|
Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • Tabrecta (capmatinib)
2years
Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma (ELCC 2022)
One patient had acquired EGFR T790M, STRN-ALK fusion, and EGFR amplification after gefitinib progression and was shortly resistant to osimertinib with MET amplification. The other patient developed to acquired EGFR T790M and MET amplification post-dacomitinib and acquired CCDC6-RET fusion after 4-month osimertinib treatment...The T790M accompanying diver gene resistance will be a new subtype after EGFR-TKIs progression and needs effective treatment options. Legal entity responsible for the study The authors.
Clinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin)
|
EGFR mutation • HER-2 amplification • MET amplification • EGFR T790M • RET fusion • EGFR amplification • ALK fusion • CCDC6-RET fusion • KRAS G12 • KRAS amplification • STRN-ALK fusion • ALK amplification • EGFR T790M + HER-2 amplification • EGFR T790M + MET amplification
|
Tagrisso (osimertinib) • gefitinib • Vizimpro (dacomitinib)
2years
Phase II Study of Lorlatinib in Patients with ROS1-Rearranged Lung Cancer with CNS Progression on Crizotinib (IASLC-TTLC 2022)
No grade 5 adverse events were observed. The study was terminated early after enrollment of 16 of 22 planned patients due to the commercial availability of off-label lorlatinib.Conclusion s : The CNS-penetrant next-generation ROS1 inhibitor lorlatinib is an effective salvage therapy for patients experiencing isolated CNS progression on crizotinib.
Clinical • P2 data
|
RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • ROS1 fusion • CCDC6-RET fusion • ROS1 rearrangement • ROS1 G2032R • ROS1 L2086F • ROS1 G2032R + ROS1 L2086F
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
over2years
NTRK- and RET-fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. (PubMed, J Clin Invest)
In pediatric fusion-oncogene PTC cases with 131I-refractory advanced disease, selective fusion-directed therapy may restore radioiodine avidity and lead to a dramatic tumor response, underscoring the importance of molecular testing in pediatric PTC patients.
Clinical • Journal
|
ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • CCDC6 (Coiled-Coil Domain Containing 6) • DICER1 (Dicer 1 Ribonuclease III) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • BRAF V600 • NTRK1 fusion • RET fusion • ALK fusion • CCDC6-RET fusion • TPR-NTRK1 fusion
|
Vitrakvi (larotrectinib) • Retevmo (selpercatinib)
almost3years
A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1 lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations. (PubMed, Lung Cancer)
Further studies are warranted to establish the role of co-occurring NF1/TP53 mutations as a positive predictive biomarker for pembrolizumab in NSCLC harboring RET fusion genes.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • NF1 (Neurofibromin 1) • CCDC6 (Coiled-Coil Domain Containing 6)
|
PD-L1 expression • TP53 mutation • EGFR mutation • PD-L1 overexpression • RET fusion • NF1 mutation • RET mutation • CCDC6-RET fusion
|
Keytruda (pembrolizumab)
almost3years
[VIRTUAL] Addition of selpercatinib to overcome osimertinib resistance in non-small cell lung cancer (NSCLC) with acquired RET fusion detected in ctDNA at very low allele frequency. (ASCO 2021)
A 37-year-old woman with stage IVB adenocarcinoma of lung with osseous, hepatic and brain metastases initially received one cycle of carboplatin, pemetrexed and pembrolizumab...The treatment regimen was switched to atezolizumab, bevacizumab, paclitaxel and carboplatin combination therapy... It has been reported that co-occurring RET fusions in NSCLC patients with EGFR mutations may contribute to acquired resistance to EGFR inhibitors . Several successful cases of cabozantinib, a non-selective RET inhibitor, or pralsetinib, a selective RET inhibitor combined with EGFR inhibitor, have been reported to aid in overcoming the acquired resistance to EGFR inhibitors . To date, there has been no report of clinical benefit in adding a RET inhibitor based on ctDNA detection of RET fusion with minute variant allele frequency .
PD(L)-1 Biomarker • Circulating tumor DNA
|
RET (Ret Proto-Oncogene)
|
EGFR mutation • EGFR exon 19 deletion • RET fusion • CCDC6-RET fusion
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • pemetrexed • Gavreto (pralsetinib)
almost3years
[VIRTUAL] Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP). (ASCO 2021)
Funding: Foundation Medicine Background: The emergence of osimertinib (osi) as standard of care therapy for EGFR-mutant NSCLC has led to investigations into understanding and overcoming drug resistance... Osi resistance in EGFR-mutant NSCLC is a poor prognosis condition . EGFR C797S is a recurring resistance mut which, in a minority of cases, can co-occur with alternate on and off target resistance muts detected with tissue and liquid biopsy.
IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RET (Ret Proto-Oncogene) • FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin)
|
BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • RET fusion • FGFR3-TACC3 fusion • ALK fusion • EGFR C797S • CCDC6-RET fusion • EGFR S768I • BRAF fusion • EGFR G719A • FGFR3 fusion • STRN-ALK fusion • EGFR G724S • EGFR L718Q • EGFR G796S
|
Tagrisso (osimertinib)
over3years
Potential unreliability of uncommon ALK/ROS1/RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC. (PubMed, J Thorac Oncol)
Uncommon ALK/ROS1/RET genomic breakpoint is an unreliable predictor of matched targeted therapy efficacy. Functional validation by RNA or protein assay may add value for accurate detection and interpretation of rare fusions.
Clinical • Journal
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4) • KIF5B (Kinesin Family Member 5B) • CD74 (CD74 Molecule) • CCDC6 (Coiled-Coil Domain Containing 6) • TPM3 (Tropomyosin 3) • SDC4 (Syndecan 4)
|
ALK positive • RET fusion • ALK fusion • ROS1 fusion • CCDC6-RET fusion • SDC4-ROS1 fusion
|
Xalkori (crizotinib)
over3years
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. (PubMed, Ann Oncol)
RET mutations at the solvent front and the hinge are resistant to both drugs. Selpercatinib and pralsetinib use an unconventional mode to bind RET that avoids the interference from gatekeeper mutations but is vulnerable to non-gatekeeper mutations.
Journal
|
RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • RET mutation • CCDC6-RET fusion
|
Retevmo (selpercatinib) • Gavreto (pralsetinib)
over3years
Glioblastomas harboring gene fusions detected by next-generation sequencing. (PubMed, Brain Tumor Pathol)
Additionally, we described two novel cases of CCDC6-RET fusion in glioma. Collectively, our findings indicate that targetable gene fusions are associated with aggressive biological behavior and can aid the clinical treatment strategy for glioma patients.
Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • TERT (Telomerase Reverse Transcriptase) • CCDC6 (Coiled-Coil Domain Containing 6) • ATRX (ATRX Chromatin Remodeler) • AKT3 (V-akt murine thymoma viral oncogene homolog 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
TP53 mutation • RET fusion • EGFR amplification • PTEN mutation • CCDC6-RET fusion • ATRX mutation • EGFR exon 2-7 deletion + EGFR amplification • EGFR mutation + PTEN mutation • MET fusion
over3years
Molecular characterisation and clinical outcomes in RET rearranged non-small cell lung cancer (NSCLC). (PubMed, J Thorac Oncol)
In RET rearranged NSCLC, selective RET TKI therapy is associated with improved survival outcomes, especially in CCDC6-RET positive patients. Immunotherapy has poor efficacy. NGS and FISH testing methods may also result in significant discordance.
Clinical • Clinical data • Journal
|
RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • KIF5B-RET fusion • CCDC6-RET fusion • RET rearrangement • RET positive
almost4years
[VIRTUAL] Complete response to selpercatinib (LOXO-292), a highly selective RET inhibitor, in a patient with RET fusion-positive breast cancer (AACR-II 2020)
Consistent with local standard of care, she received treatment with tamoxifen plus goserelin from March through June 2019, but these were discontinued for progression in the right breast and new lesions in the left lower lung... Selpercatinib demonstrated anti-tumor activity in a patient with RET fusion-positive breast cancer. To our knowledge, this is the first report of a breast cancer patient with a sustained response to selective, RET-targeted therapy and adds to the diversity of RET fusion-positive tumor types that may benefit from selective RET inhibition.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • CCDC6-RET fusion • RET positive
|
tamoxifen • Retevmo (selpercatinib) • goserelin acetate